The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology

ABSTRACT

In this article, after providing a description of the technique of brain positron emission tomography (PET), the review focuses on the application of PET and other recent advances of neuroimaging in understanding the structural, pathophysiological, and pharmacological changes associated with Parkinson's disease (PD). In early cases of PD, demonstration of the presence of nigral structural abnormalities with transcranial sonography and striatal dopaminergic dysfunction with functional imaging provides a rationale for the use of dopaminergic medications. The presence of altered striatal signal with diffusion-weighted magnetic resonance imaging (DWI) or reduced lentiform nucleus glucose metabolism with fluorodeoxyglucose PET suggests the presence of an atypical PD variant. Finally, the value of functional imaging as a biomarker for following the progression of PD and for understanding mechanisms of dementia when present is debated.

KEYWORDS

PET - SPECT - MRI - Parkinson - dementia

REFERENCES

• 1 Fearnley J M, Lees A J. Ageing and Parkinson's disease: substantia nigra regional selectivity.  Brain. 1991;  114 2283-2301
• 2 Gasser T. Update on the genetics of Parkinson's disease.  Mov Disord. 2007;  22 (suppl 17) S343-S350
• 3 Siderowf A, Stern M B. Preclinical diagnosis of Parkinson's disease: are we there yet?.  Curr Neurol Neurosci Rep. 2006;  6 295-301
• 4 Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.  J Neurol. 2001;  248 684-689
• 5 Brooks D J. Neuroimaging in Parkinson's disease.  NeuroRx. 2004;  1 243-254
• 6 Laruelle M, Baldwin R M, Malison R T et al.. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.  Synapse. 1993;  13 295-309
• 7 Eidelberg D, Moeller J R, Dhawan V et al.. The metabolic topography of parkinsonism.  J Cereb Blood Flow Metab. 1994;  14 783-801
• 8 Feigin A, Fukuda M, Dhawan V et al.. Metabolic correlates of levodopa response in Parkinson's disease.  Neurology. 2001;  57 2083-2088
• 9 Eckert T, Barnes A, Dhawan V et al.. FDG PET in the differential diagnosis of parkinsonian disorders.  Neuroimage. 2005;  26 912-921
• 10 Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging.  AJNR Am J Neuroradiol. 2000;  21 697-701
• 11 Hu M T, White S J, Herlihy A H et al.. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease.  Neurology. 2001;  56 1195-1200
• 12 Minati L, Grisoli M, Carella F et al.. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging.  AJNR Am J Neuroradiol. 2007;  28 309-313
• 13 Michaeli S, Oz G, Sorce D J et al.. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.  Mov Disord. 2007;  22 334-340
• 14 Geng D Y, Li Y X, Zee C S. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.  Neurosurgery. 2006;  58 256-262
• 15 Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging.  Neurol Sci. 2003;  24(suppl 1) S35-S37
• 16 Schrag A, Good C D, Miszkiel K et al.. Differentiation of atypical parkinsonian syndromes with routine MRI.  Neurology. 2000;  54 697-702
• 17 Schocke M F, Seppi K, Esterhammer R et al.. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD.  Neurology. 2002;  58 575-580
• 18 Seppi K, Schocke M F, Esterhammer R et al.. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.  Neurology. 2003;  60 922-927
• 19 Nicoletti G, Lodi R, Condino F et al.. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.  Brain. 2006;  129(Pt 10) 2679-2687
• 20 Paviour D C, Thornton J S, Lees A J, Jager H R. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.  Mov Disord. 2007;  22 68-74
• 21 Stockner H, Sojer M et al.. Midbrain sonography in patients with essential tremor.  Mov Disord. 2007;  22 414-417
• 22 Walter U, Hoeppner J, Prudente-Morrissey L et al.. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.  Brain. 2007;  130(Pt 7) 1799-1807
• 23 Prestel J, Schweitzer K J, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease.  Mov Disord. 2006;  21 1763-1765
• 24 Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.  Mov Disord. 2005;  20 383-385
• 25 Berg D, Roggendorf W, Schroder U et al.. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.  Arch Neurol. 2002;  59 999-1005
• 26 Walter U, Dressler D, Probst T et al.. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease.  Arch Neurol. 2007;  64 1635-1640
• 27 Morrish P K, Sawle G V, Brooks D J. Clinical and [18F]dopa PET findings in early Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1995;  59 597-600
• 28 Marek K L, Seibyl J P, Zoghbi S S et al.. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.  Neurology. 1996;  46 231-237
• 29 Benamer T S, Patterson J, Grosset D G et al.. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: The [123I]-FP-CIT Study Group.  Mov Disord. 2000;  15 503-510
• 30 Jennings D L, Seibyl J P, Oakes D et al.. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis.  Arch Neurol. 2004;  61 1224-1229
• 31 Catafau A M, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes.  Mov Disord. 2004;  19 1175-1182
• 32 Tolosa E, Borght T V, Moreno E. Accuracy of DaTSCAN ((123)I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study.  Mov Disord. 2007;  22 2346-2351
• 33 Hughes A J, Ben-Shlomo Y, Daniel S E, Lees A J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study.  Neurology. 1992;  42 1142-1146
• 34 Fahn S, Oakes D, Shoulson I et al.. Levodopa and the progression of Parkinson's disease.  N Engl J Med. 2004;  351 2498-2508
• 35 Parkinson Study Group . Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.  JAMA. 2002;  287 1653-1661
• 36 Whone A L, Watts R L, Stoessl J et al.. Slower progression of PD with ropinirol versus L-dopa: the REAL-PET study.  Ann Neurol. 2003;  54 93-101
• 37 Marshall V L, Patterson J, Hadley D M, Grosset K A, Grosset D G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.  Nucl Med Commun. 2006;  27 933-937
• 38 Ahlskog J E. Slowing Parkinson's disease progression: recent dopamine agonist trials.  Neurology. 2003;  60 381-389
• 39 Jenner P, Olanow C W. Understanding cell death in Parkinson's disease.  Ann Neurol. 1998;  44 S72-S84
• 40 Schapira A H, Olanow C W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.  JAMA. 2004;  291 358-364
• 41 Emre M. Dementia associated with Parkinson's disease.  Lancet Neurol. 2003;  2 229-237
• 42 Summerfield C, Junque C, Tolosa E et al.. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.  Arch Neurol. 2005;  62 281-285
• 43 Ramirez-Ruiz B, Marti M J, Tolosa E et al.. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.  J Neurol. 2005;  252 1345-1352
• 44 Burton E J, McKeith I G, Burn D J, O'Brien J T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging.  Mov Disord. 2005;  20 1571-1576
• 45 Foster N L, Chase T N, Fedio P et al.. Alzheimer's disease: focal cortical changes shown by positron emission tomography.  Neurology. 1983;  33 961-965
• 46 Peppard R F, Martin W RW, Carr G D et al.. Cerebral glucose metabolism in Parkinson's disease with and without dementia.  Arch Neurol. 1992;  49 1262-1268
• 47 Vander-Borght T, Minoshima S, Giordani B et al.. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity.  J Nucl Med. 1997;  38 797-802
• 48 Yong S W, Yoon J K, An Y S, Lee P H. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies.  Eur J Neurol. 2007;  14 1357-1362
• 49 Hu M TM, Taylor-Robinson S D, Chaudhuri K R et al.. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18FDG)-PET study.  Brain. 2000;  123 340-352
• 50 Walker Z, Costa D C, Walker R W et al.. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.  J Neurol Neurosurg Psychiatry. 2002;  73 134-140
• 51 Walker Z, Jaros E, Walker R W et al.. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy.  J Neurol Neurosurg Psychiatry. 2007;  78 1176-1181
• 52 O'Brien J T, Colloby S, Fenwick J et al.. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.  Arch Neurol. 2004;  61 919-925
• 53 Ito K, Nagano-Saito A, Kato T et al.. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.  Brain. 2002;  125(Pt 6) 1358-1365
• 54 Kuhl D E, Minoshima S, Fessler J A et al.. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.  Ann Neurol. 1996;  40 399-410
• 55 Hilker R, Thomas A V, Klein J C et al.. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.  Neurology. 2005;  65 1716-1722
• 56 Bohnen N I, Kaufer D I, Hendrickson R et al.. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.  J Neurol. 2006;  253 242-247
• 57 Bacskai B J, Frosch M P, Freeman S H et al.. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.  Arch Neurol. 2007;  64 431-434
• 58 Klunk W E, Engler H, Nordberg A et al.. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol. 2004;  55 306-319
• 59 Edison P, Archer H A, Hinz R et al.. Amyloid, hypometabolism, and cognition in Alzheimer disease—an [11C]PIB and [18F]FDG PET study.  Neurology. 2007;  68 501-508
• 60 Rowe C C, Ng S, Ackermann U et al.. Imaging beta-amyloid burden in aging and dementia.  Neurology. 2007;  68 1718-1725